(AOF) – Implanet announces a turnover of 1.53 million euros in the third quarter, down 17% year-on-year. The medical technology company specializing in implants intended for orthopedic surgery and in the distribution of technological medical equipment specifies that it achieved a turnover of 5.81 million euros over the first nine months of 2023, to compare to the 5.97 million euros achieved over the same period in 2022.
As of September 30, 2023, the company had cash of 0.43 million euros, insufficient “in view of the company’s current operational development plan to finance the activity over the next twelve months”.
The company’s Board of Directors, in its meeting of October 9, 2023, therefore authorized the establishment of short-term financing of a maximum amount of 1.3 million euros in nominal value in dry bonds with of two non-shareholder investors of the company.
Implanet specifies that “based on current cash flow forecasts and in the absence of obtaining new sources of financing, the drawing of the first tranche allows the company to be financed until December 31, 2023”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.